News

Eli Lilly (NYSE: LLY) has crushed the market over the past decade, largely thanks to breakthroughs within its core therapeutic area. Some might think it's too late to invest in the stock. Eli Lilly

Vertex Pharmaceuticals (NASDAQ: VRTX) is a great example of a biotech success story. The company has developed strength in a specialty area and, thanks to that, has delivered a track record of

Vertex Pharmaceuticals (NASDAQ: VRTX) has underperformed the market over the past year, rising less than 2%. The biotech, known for its cystic fibrosis (CF) treatments, is scheduled to report

Vertex Pharmaceuticals (NASDAQ: VRTX) experienced several setbacks last year, sometimes following quarterly updates that weren't as strong as the market expected, or during which it also reported

Pfizer (NYSE: PFE) has been an underwhelming stock to own in recent years. Question marks about its growth and how it will do in the future, as it faces multiple patent cliffs, have resulted in

Shares of UnitedHealth Group (NYSE: UNH) have been falling rapidly after the company reported its latest earnings numbers. This is even after an already tough year in 2025, when the health insurance

Zoetis (NYSE: ZTS) tanked after its November earnings release. Will history repeat itself pre-market on Feb. 12, when the animal healthcare company releases results for the fourth quarter of 2025

Earnings seasons can sometimes be rough. We're seeing it this time around with several AI stocks. Advanced Micro Devices' (NASDAQ: AMD) and Microsoft's (NASDAQ: MSFT) shares plunged after its recent

Telecom powerhouse AT&T (NYSE: T) is certainly a respectable company and a great dividend payer. But is it a growth stock? Hardly.

Except, for the foreseeable future, it's going to be putting up

Eli Lilly's (NYSE: LLY) stock has risen 225% over the past three years. That trounces the S&P 500's (SNPINDEX: ^GSPC) gain of 66% over the same span.

If you weren't on board for that ride, you may

AT&T (NYSE: T) cut its dividend by nearly 50% in 2022. That move followed the spinoff of WarnerMedia, undoing what, in hindsight, proved to be a disastrous acquisition. Those two decisions set AT&T

After underperforming broader equities over the past few years, will the healthcare sector finally rebound and deliver above-average returns from here on out? That's hard to say. Whatever the case

Cathie Wood, the CEO of Ark Invest, is known for investing in companies with strong innovative potential. That includes biotechs that specialize in gene editing, a group of techniques that could

One of the healthier stocks on the market Friday was veteran biotech Biogen (NASDAQ: BIIB). The company unveiled its final set of fundamentals for 2025, and it crushed analyst estimates for both

With healthcare's status as a recession-resistant industry, healthcare stocks can be a great place for dividend investors to find companies paying out steady, consistent dividends. However, it's not

On February 4, Triton Wealth Management, PLLC reported selling 481,779 shares of Knight-Swift Transportation Holdings (NYSE:KNX), an estimated $22.58 million trade based on quarterly average

Tejara Capital Ltd disclosed a buy of 69,700 Teleflex (NYSE:TFX) shares in a February 5 SEC filing, with an estimated transaction value of $8.45 million based on quarterly average pricing.

According

Royal Caribbean (NYSE: RCL) is set to launch a river cruise business through its upscale Celebrity brand, and demand has been so strong that the cruise line doubled its expected fleet size from 10

In today's video, I discuss recent updates affecting Advanced Micro Devices (NASDAQ: AMD) and other AI stocks. To learn more, check out the short video, consider subscribing, and click the special

Cathie Wood has been getting busy on the trading floor. The recent market volatility means opportunity, and the co-founder, CEO and chief investment officer of Ark Invest doesn't shy away from

Shares of CVS Health (NYSE: CVS) have been declining recently as a potentially lower-than-expected increase in Medicare Advantage rates has investors worried about companies with exposure to health

Axsome Therapeutics (NASDAQ: AXSM) has been a red-hot stock to own over the past 12 months. During that stretch, it has soared by around 75%, dwarfing the performance of the S&P 500, which is up by

Eli Lilly's (NYSE: LLY) obesity drug, Zepbound, generated sales of $13.5 billion in 2025. Its Type 2 diabetes drug Mounjaro, which is also marketed for treating obesity outside of the U.S., Canada

If you're investing in a dividend stock, it's important to track its performance to see if there are any warning signs that might affect its ability to pay its current rate of dividends in the

Boston Scientific (NYSE:BSX), a medical-device maker for interventional specialties, closed Wednesday at $75.50, down 17.59%. The stock fell after Q4 earnings beat expectations, but cautious 2026